| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Berislav V Zlokovic | |
| P2860 | cites work | Circulating amyloid-beta peptide crosses the blood-brain barrier in aged monkeys and contributes to Alzheimer's disease lesions | Q48408756 |
| Deposition of Alzheimer's beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans | Q48476417 | ||
| Brain clearance of Alzheimer's amyloid-beta40 in the squirrel monkey: a SPECT study in a primate model of cerebral amyloid angiopathy | Q48520287 | ||
| Plaque-associated disruption of CSF and plasma amyloid-beta (Abeta) equilibrium in a mouse model of Alzheimer's disease | Q48579999 | ||
| Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease | Q48652428 | ||
| Metabolic regulation of brain Abeta by neprilysin | Q48869458 | ||
| Coaxing the LDL receptor family into the fold. | Q52109257 | ||
| Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE | Q22010705 | ||
| Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis | Q22254188 | ||
| The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics | Q27860914 | ||
| Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo | Q28131779 | ||
| Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis | Q28217930 | ||
| The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease | Q30432239 | ||
| beta-Amyloid efflux mediated by p-glycoprotein | Q31962046 | ||
| Clearing the brain's amyloid cobwebs | Q34099588 | ||
| Amyloidosis and Alzheimer's disease | Q34161041 | ||
| Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice | Q35747037 | ||
| Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers | Q37633630 | ||
| The cytoplasmic domain of the LDL receptor-related protein regulates multiple steps in APP processing | Q39665687 | ||
| RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain | Q44479225 | ||
| Genetic association of the low-density lipoprotein receptor-related protein gene (LRP), an apolipoprotein E receptor, with late-onset Alzheimer's disease | Q44672537 | ||
| Substitution at codon 22 reduces clearance of Alzheimer's amyloid-beta peptide from the cerebrospinal fluid and prevents its transport from the central nervous system into blood | Q46087723 | ||
| Lipoprotein-free amyloidogenic peptides in plasma are elevated in patients with sporadic Alzheimer's disease and Down's syndrome | Q48231764 | ||
| High levels of circulating Abeta42 are sequestered by plasma proteins in Alzheimer's disease | Q48233908 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | blood–brain barrier | Q221694 |
| P304 | page(s) | 807-811 | |
| P577 | publication date | 2004-05-01 | |
| P1433 | published in | Journal of Neurochemistry | Q6295643 |
| P1476 | title | Clearing amyloid through the blood-brain barrier | |
| P478 | volume | 89 |
| Q37403948 | A Role for P-Glycoprotein in Clearance of Alzheimer Amyloid β -Peptide from the Brain |
| Q38376174 | A Simulation Model of Periarterial Clearance of Amyloid-β from the Brain |
| Q35070713 | A dynamic relationship between intracellular and extracellular pools of Abeta |
| Q35062331 | ABCB1 genotypes and haplotypes in patients with dementia and age-matched non-demented control patients |
| Q64110083 | Acute neuropathological consequences of short-term mechanical ventilation in wild-type and Alzheimer's disease mice |
| Q48222289 | Aging alters mRNA expression of amyloid transporter genes at the blood-brain barrier |
| Q33617218 | Alteration of Aβ metabolism-related molecules in predementia induced by AlCl3 and D-galactose |
| Q40196236 | Alterations in the Levels of Amyloid-β, Phospholipid Hydroperoxide, and Plasmalogen in the Blood of Patients with Alzheimer's Disease: Possible Interactions between Amyloid-β and These Lipids |
| Q36491332 | Altered morphology and 3D architecture of brain vasculature in a mouse model for Alzheimer's disease |
| Q37253310 | Alzheimer's disease and blood-brain barrier function-Why have anti-beta-amyloid therapies failed to prevent dementia progression? |
| Q37422795 | Alzheimer's disease and the Blood-Brain Barrier: Past, Present and Future |
| Q42413568 | Amyloid and tau in the brain in sporadic Alzheimer's disease: defining the chicken and the egg. |
| Q53415989 | Amyloid efflux transporter expression at the blood-brain barrier declines in normal aging. |
| Q34482602 | Amyloid β levels in human red blood cells |
| Q35183396 | Amyloid-beta transporter expression at the blood-CSF barrier is age-dependent |
| Q37773826 | Amyloid-modifying therapies for Alzheimer's disease: therapeutic progress and its implications |
| Q34548700 | Amyloid-ß-directed immunotherapy for Alzheimer's disease |
| Q35166482 | Amyloid-β efflux from the central nervous system into the plasma |
| Q48569188 | Another crack in the edifice of the brain-blood interface |
| Q37831912 | Antibody-based therapy in Alzheimer's disease |
| Q37124428 | Apolipoprotein E, amyloid-beta, and blood-brain barrier permeability in Alzheimer disease |
| Q36512147 | Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease. |
| Q34497951 | Apolipoprotein E: From lipid transport to neurobiology |
| Q35839729 | Attenuation of neuroinflammation and Alzheimer's disease pathology by liver x receptors |
| Q38104717 | Beta-amyloidolysis and glutathione in Alzheimer's disease |
| Q35157420 | Blocking the apolipoprotein E/amyloid-beta interaction as a potential therapeutic approach for Alzheimer's disease |
| Q41108837 | Blood-brain barrier and Alzheimer's. |
| Q38752185 | Blood-brain barrier and blood-cerebrospinal fluid barrier in normal and pathological conditions |
| Q38154683 | Blood-brain-barriers in aging and in Alzheimer's disease |
| Q38937481 | Brain microvascular pericytes are immunoactive in culture: cytokine, chemokine, nitric oxide, and LRP-1 expression in response to lipopolysaccharide |
| Q37624992 | Chapter 7: Cell protective functions of secretory Clusterin (sCLU). |
| Q60693600 | Choroid Plexus Megalin Is Involved in Neuroprotection by Serum Insulin-Like Growth Factor I |
| Q36566738 | Choroidal Thickness in Patients with Mild Cognitive Impairment and Alzheimer's Type Dementia |
| Q37812906 | Chronic mild cerebrovascular dysfunction as a cause for Alzheimer's disease? |
| Q34960461 | Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease |
| Q37239081 | Clinico-pathologic function of cerebral ABC transporters - implications for the pathogenesis of Alzheimer's disease |
| Q45300233 | Comparison of Efficacy of Preventive and Therapeutic Vaccines Targeting the N Terminus of β-Amyloid in an Animal Model of Alzheimer's Disease |
| Q36076645 | Correlation of CT perfusion and CT volumetry in patients with Alzheimer's disease |
| Q37310176 | Current state of immunotherapy for Alzheimer's disease |
| Q37737296 | Current therapeutic targets for the treatment of Alzheimer's disease |
| Q33643056 | Degradation of soluble and fibrillar amyloid beta-protein by matrix metalloproteinase (MT1-MMP) in vitro |
| Q37219298 | Dementia of the Alzheimer type |
| Q35085065 | Dense-core plaques in Tg2576 and PSAPP mouse models of Alzheimer's disease are centered on vessel walls |
| Q37446178 | Depletion of vitamin E increases amyloid beta accumulation by decreasing its clearances from brain and blood in a mouse model of Alzheimer disease |
| Q37353187 | Developing drugs that can cross the blood-brain barrier: applications to Alzheimer's disease |
| Q36640414 | Disease modifying therapy for AD? |
| Q48260410 | Does the difference between PART and Alzheimer's disease lie in the age-related changes in cerebral arteries that trigger the accumulation of Aβ and propagation of tau? |
| Q48489678 | Drug transport into the central nervous system: using newer findings about the blood-brain barriers |
| Q33793048 | Early-onset formation of parenchymal plaque amyloid abrogates cerebral microvascular amyloid accumulation in transgenic mice |
| Q37578319 | Ectodomain shedding of the receptor for advanced glycation end products: a novel therapeutic target for Alzheimer's disease |
| Q45307020 | Effects of chronic glucocorticoid administration on insulin-degrading enzyme and amyloid-beta peptide in the aged macaque. |
| Q37589619 | Efficacy and Safety of Plasma Exchange with 5% Albumin to Modify Cerebrospinal Fluid and Plasma Amyloid-β Concentrations and Cognition Outcomes in Alzheimer's Disease Patients: A Multicenter, Randomized, Controlled Clinical Trial |
| Q37337462 | Efflux transport of serum amyloid P component at the blood-brain barrier |
| Q46222013 | Enhanced proteolytic clearance of plasma Aβ by peripherally administered neprilysin does not result in reduced levels of brain Aβ in mice. |
| Q42657132 | Expression and function of Abcg4 in the mouse blood-brain barrier: role in restricting the brain entry of amyloid-β peptide |
| Q34632017 | Ginsenoside Rg1 decreases Aβ(1-42) level by upregulating PPARγ and IDE expression in the hippocampus of a rat model of Alzheimer's disease |
| Q36961152 | Heat shock proteins and amateur chaperones in amyloid-Beta accumulation and clearance in Alzheimer's disease |
| Q33355985 | Human microglial cells synthesize albumin in brain |
| Q24646788 | Human serum albumin inhibits Abeta fibrillization through a "monomer-competitor" mechanism |
| Q53376168 | IgG-assisted age-dependent clearance of Alzheimer's amyloid beta peptide by the blood-brain barrier neonatal Fc receptor. |
| Q52148224 | Immunohistochemical analysis of transporters related to clearance of amyloid-β peptides through blood-cerebrospinal fluid barrier in human brain. |
| Q41209061 | Immunohistochemical detection of receptor-associated protein in normal human brain and Alzheimer's disease |
| Q27319555 | Impact of age on the cerebrovascular proteomes of wild-type and Tg-SwDI mice |
| Q27023953 | Inflammatory events at blood-brain barrier in neuroinflammatory and neurodegenerative disorders: implications for clinical disease |
| Q43074615 | Kaolin-induced chronic hydrocephalus accelerates amyloid deposition and vascular disease in transgenic rats expressing high levels of human APP. |
| Q38289396 | LRP promotes endocytosis and degradation, but not transcytosis, of the amyloid-beta peptide in a blood-brain barrier in vitro model |
| Q42321517 | LRP-1 and LRP-2 receptors function in the membrane neuron. Trafficking mechanisms and proteolytic processing in Alzheimer's disease |
| Q33960315 | Lack of LDL receptor enhances amyloid deposition and decreases glial response in an Alzheimer's disease mouse model |
| Q34096338 | Lipid rafts participate in aberrant degradative autophagic-lysosomal pathway of amyloid-beta peptide in Alzheimer's disease |
| Q37439528 | Lipopolysaccharide alters the blood-brain barrier transport of amyloid beta protein: a mechanism for inflammation in the progression of Alzheimer's disease |
| Q36202900 | Lipoprotein receptor-related protein-1 mediates amyloid-beta-mediated cell death of cerebrovascular cells |
| Q35754176 | Liver production of sulfamidase reverses peripheral and ameliorates CNS pathology in mucopolysaccharidosis IIIA mice |
| Q35020981 | Low-density lipoprotein receptor-related protein is decreased in optic neuropathy of Alzheimer disease |
| Q30275974 | Lymphatics in Neurological Disorders: A Neuro-Lympho-Vascular Component of Multiple Sclerosis and Alzheimer's Disease? |
| Q35946613 | Macromolecules involved in production and metabolism of beta-amyloid at the brain barriers |
| Q30671407 | Mapping the interactions between the Alzheimer's Aβ-peptide and human serum albumin beyond domain resolution |
| Q47587456 | Matrix metalloproteinases expressed by astrocytes mediate extracellular amyloid-beta peptide catabolism. |
| Q33444709 | Metabolites of cerebellar neurons and hippocampal neurons play opposite roles in pathogenesis of Alzheimer's disease. |
| Q43753603 | MicroRNA-146a represses LRP2 translation and leads to cell apoptosis in Alzheimer's disease |
| Q46691360 | Microglial phagocytosis induced by fibrillar beta-amyloid and IgGs are differentially regulated by proinflammatory cytokines. |
| Q36190786 | Mining the secrets of the CSF: developing biomarkers of neurodegeneration |
| Q44115983 | Modeling effect of a γ-secretase inhibitor on amyloid-β dynamics reveals significant role of an amyloid clearance mechanism |
| Q48710938 | Modulation of Amyloid-β1-40 Transport by ApoA1 and ApoJ Across an in vitro Model of the Blood-Brain Barrier |
| Q42149893 | Modulation of iron metabolism in aging and in Alzheimer's disease: relevance of the choroid plexus |
| Q48421288 | Molecular chaperons, amyloid and preamyloid lesions in the BRI2 gene-related dementias: a morphological study |
| Q36532822 | Muscle-directed anti-Aβ single-chain antibody delivery via AAV1 reduces cerebral Aβ load in an Alzheimer's disease mouse model |
| Q28570444 | Mutation of active site residues of insulin-degrading enzyme alters allosteric interactions |
| Q48142392 | Neurogenic effects of β-amyloid in the choroid plexus epithelial cells in Alzheimer's disease |
| Q36942721 | Neurovascular unit in chronic pain |
| Q25256570 | Novel Abeta peptide immunogens modulate plaque pathology and inflammation in a murine model of Alzheimer's disease |
| Q36714447 | Novel modulators of amyloid-beta precursor protein processing |
| Q57184152 | Nucleoside-5'-phosphorothioate analogues are biocompatible antioxidants dissolving efficiently amyloid beta-metal ion aggregates |
| Q37533199 | Ocular changes in TgF344-AD rat model of Alzheimer's disease |
| Q37070169 | Ovariectomy increases neuronal amyloid-beta binding alcohol dehydrogenase level in the mouse hippocampus |
| Q37686110 | PPARγ agonists regulate bidirectional transport of amyloid-β across the blood-brain barrier and hippocampus plasticity in db/db mice |
| Q42115937 | PPARγ coactivator-1α (PGC-1α) protects neuroblastoma cells against amyloid-beta (Aβ) induced cell death and neuroinflammation via NF-κB pathway |
| Q42540801 | Partial Loss of the Glutamate Transporter GLT-1 Alters Brain Akt and Insulin Signaling in a Mouse Model of Alzheimer's Disease |
| Q38007947 | Pathological alteration in the choroid plexus of Alzheimer's disease: implication for new therapy approaches |
| Q42703052 | Peripheral amyloid-beta levels regulate amyloid-beta clearance from the central nervous system |
| Q47593479 | Perspectives of Alzheimer's disease treatments |
| Q37131933 | Plasma Clusterin and the CLU Gene rs11136000 Variant Are Associated with Mild Cognitive Impairment in Type 2 Diabetic Patients |
| Q48383092 | Potential inplications of endogenous aldehydes in beta-amyloid misfolding, oligomerization and fibrillogenesis |
| Q48496983 | Prevalence and impact of cerebrovascular pathology in Alzheimer's disease and parkinsonism |
| Q44257894 | Processing of the platelet amyloid precursor protein in the mild cognitive impairment (MCI). |
| Q41869540 | Protein kinase C-regulated aβ production and clearance |
| Q33841564 | Receptor for advanced glycation end products is upregulated in optic neuropathy of Alzheimer's disease |
| Q33744970 | Reduction of low-density lipoprotein receptor-related protein (LRP1) in hippocampal neurons does not proportionately reduce, or otherwise alter, amyloid deposition in APPswe/PS1dE9 transgenic mice |
| Q37069278 | Regulation of beta-amyloid levels in the brain of cholesterol-fed rabbit, a model system for sporadic Alzheimer's disease |
| Q34055011 | Role of vascular risk factors and vascular dysfunction in Alzheimer's disease |
| Q43478841 | Serum beta-amyloid correlates with neuropsychological impairment. |
| Q47165213 | Suppression of Alzheimer's disease-related phenotypes by the heat shock protein 70 inducer, geranylgeranylacetone, in APP/PS1 transgenic mice via the ERK/p38 MAPK signaling pathway |
| Q27316689 | Systemic administration of Abeta mAb reduces retinal deposition of Abeta and activated complement C3 in age-related macular degeneration mouse model |
| Q37954456 | Systemic and central immunity in Alzheimer's disease: therapeutic implications |
| Q53387554 | TREM1: A Potential Therapeutic Target For Alzheimer's Disease. |
| Q38738049 | The Choroid Plexus in Healthy and Diseased Brain |
| Q34493230 | The absence of myelin basic protein promotes neuroinflammation and reduces amyloid β-protein accumulation in Tg-5xFAD mice |
| Q37695577 | The choroid plexus removes beta-amyloid from brain cerebrospinal fluid |
| Q30892053 | The choroid plexus response to a repeated peripheral inflammatory stimulus |
| Q38252274 | The contribution of astrocytes to Alzheimer's disease. |
| Q46923380 | The contribution of cerebral vascular semicarbazide-sensitive amine oxidase to cerebral amyloid angiopathy in Alzheimer's disease |
| Q38016800 | The development of effective biomarkers for Alzheimer's disease: a review |
| Q48203580 | The expression of LDL receptor in vessels with blood-brain barrier impairment in a stroke-prone hypertensive model |
| Q21202840 | The generation and function of soluble apoE receptors in the CNS |
| Q34442604 | The impact of microglial activation on blood-brain barrier in brain diseases. |
| Q38121608 | The potential mechanisms of Aβ-receptor for advanced glycation end-products interaction disrupting tight junctions of the blood-brain barrier in Alzheimer's disease |
| Q50082084 | The relationship between cholesterol level and Alzheimer's disease-associated APP proteolysis/Aβ metabolism |
| Q34573524 | The significance of neuroinflammation in understanding Alzheimer's disease. |
| Q42484451 | Transcriptome signature of the adult mouse choroid plexus |
| Q33262322 | Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system |
| Q28301724 | What is the dominant Abeta species in human brain tissue? A review |
| Q21284467 | beta-Amyloid degradation and Alzheimer's disease |
| Q49240647 | α-Synuclein Aggregated with Tau and β-Amyloid in Human Platelets from Healthy Subjects: Correlation with Physical Exercise. |
| Q38831103 | α-Synuclein Aggregates with β-Amyloid or Tau in Human Red Blood Cells: Correlation with Antioxidant Capability and Physical Exercise in Human Healthy Subjects |
| Q47672665 | β-Amyloid and the Pathomechanisms of Alzheimer's Disease: A Comprehensive View |
Search more.